
    adverse change in the risk/benefit
  
['healthy volunteers', 'ulcerative colitis']
['bms-986184', 'placebo matching bms-986184']

        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Women of childbearing potential must have a negative serum pregnancy test within 24
             hours prior to the start of study drug

          -  Diagnosis of ulcerative colitis confirmed by endoscopic and histologic evidence (if no
             previous confirmation of diagnosis is available or if diagnosis is not conclusive, at
             time of baseline endoscopy, histology must be performed and read locally to confirm
             diagnosis)

        Exclusion Criteria:

          -  Any bacterial, fungal or viral infection, including tuberculosis, HIV, hepatitis B or
             hepatitis C

          -  Subjects with history of cancer, lymphoproliferative disease, class III or IV
             congestive heart failure, myocardial infarction, unstable angina pectoris, or any
             history of significant ocular disease such as glaucoma or retinal disease

        Other protocol defined inclusion/exclusion criteria could apply
      